Read by QxMD icon Read

Asia-Pacific Journal of Clinical Oncology

Miao-Yun Long, Fei-Yu Diao, Li-Na Peng, Lang-Ping Tan, Yue Zhu, Kai Huang, Hong-Hao Li
AIM: To explore the application of intraoperative neurological monitoring in residual thyroidectomy 5-15 days after thyroid cancer operation and the influence on postoperative serum thyroglobulin (Tg), recurrent laryngeal nerve and function of parathyroid glands. METHODS: Material of patients receiving thyroid surgery from January 2010 to December 2016 was retrospectively analyzed. Cases meeting with standards were enrolled for analysis and the patients were divided into neurological monitoring group and non-neurological monitoring group in line with the use of neurological monitoring during the operation...
May 16, 2018: Asia-Pacific Journal of Clinical Oncology
Zifan He, Ziwei Liao, Shaohua Chen, Bo Li, Zhi Yu, Gengxin Luo, Lijian Yang, Chengwu Zeng, Yangqiu Li
AIM: BCL11B overexpression is a characteristic of most T cell acute lymphoblastic leukemia (T-ALL) cases, and downregulated BCL11B in leukemic T cells inhibits cell proliferation and induces apoptosis. The purpose of this study was to analyze the miRNA expression pattern that may be related to BCL11B regulation in T-ALL. METHODS: Quantitative real-time PCR was used to detect the miRNAs miR-17-3p, miR-17-5p, miR-29c-3p, miR-92a-3p, miR-214-3p and miR-214-5p, the BCL11B expression level in peripheral blood mononuclear cells which was obtained from 17 de novo and untreated T-ALL patients, and 15 healthy individuals (HIs) served as control...
May 11, 2018: Asia-Pacific Journal of Clinical Oncology
Ting Zhang, Guiwen Guan, Tingting Chen, Jingling Jin, Lichun Zhang, Mingjie Yao, Xuewei Qi, Jun Zou, Jiacheng Chen, Fengmin Lu, Xiangmei Chen
OBJECTIVE: Several members of protocadherins (PCDHs) have been identified as tumor suppressor genes in human carcinogenesis, but little is known about PCDH19. The aim of the present study was to assess the expression and methylation of PCDH19 in hepatocellular carcinoma (HCC). METHODS: The RNA-seq data from The Cancer Genome Atlas Database were downloaded and used for analyzing PCDH19 expression in HCC patients and normal liver tissues. We collected 63 paired tumor and nontumor liver tissues from hepatitis B virus-related HCC patients...
May 11, 2018: Asia-Pacific Journal of Clinical Oncology
Fiona L Day, Emma Sherwood, Tina Y Chen, Margaret Barbouttis, Megan Varlow, Jarad Martin, Marianne Weber, Freddy Sitas, Christine Paul
AIM: Continued smoking in patients diagnosed with cancer affects treatment outcomes and overall survival. With national surveys of Australian medical oncologists (MO) and radiation oncologists (RO) we sought to determine current clinical practices, preferences and barriers in providing patient smoking cessation support. METHODS: Oncologist members of the Medical Oncology Group of Australia (n = 452) and Trans-Tasman Radiation Oncology Group (n = 230) were invited to participate in a multiple choice survey exploring smoking cessation practices and beliefs...
April 29, 2018: Asia-Pacific Journal of Clinical Oncology
Sue M Evans, Declan G Murphy, Ian D Davis, Shomik Sengupta, Ehsan Zare Borzeshi, Fanny Sampurno, Jeremy L Millar
AIM: This study aims to assess characteristics of patients with prostate cancer for whom clinical T stage category (cT) was not documented in the medical record and assess whether specialists had concordant conclusions regarding cT based on digital rectal examination (DRE) notes. METHODS: Data from the Prostate Cancer Outcome Registry - Victoria (PCOR-Vic) were interrogated. Four specialists independently assigned cT to DRE notes. Words, or part thereof, associated with agreement between clinicians were identified...
April 27, 2018: Asia-Pacific Journal of Clinical Oncology
Malinda Itchins, Sarah A Hayes, Anthony J Gill, Wendy Cooper, Rachel O'Connell, Viive M Howell, Stephen J Clarke, Nick Pavlakis
AIM: To report on the pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+NSCLC) in a real-world retrospective cohort from an Australian tertiary referral center. METHODS: Individuals with a pathological diagnosis of ALK+NSCLC via immunohistochemistry and fluorescence in situ hybridization and a radiological diagnosis of stage IV disease were eligible. Patients were identified via the Pathology Department specimen database and electronic patient chart review...
April 19, 2018: Asia-Pacific Journal of Clinical Oncology
George Hruby, Thomas Eade, Louise Emmett, Bao Ho, Ed Hsiao, Geoff Schembri, Linxin Guo, Carolyn Kwong, Julia Hunter, Keelan Byrne, Andrew Kneebone
AIM: To explore the utility of prostate specific membrane antigen (PSMA)-positron emission tomography (PET)/computed tomography (CT) in addition to conventional imaging prior to definitive external beam radiation treatment (EBRT) for prostate cancer. METHODS: All men undergoing PSMA-PET/CT prior to definitive EBRT for intermediate and high-risk prostate cancer were included in our ethics approved prospective database. For each patient, clinical and pathological results, in addition to scan results including site of PSMA positive disease and number of lesions, were recorded...
April 16, 2018: Asia-Pacific Journal of Clinical Oncology
Darren M C Poon, Tim Chan, Kuen Chan, Michelle Chan, Eric K C Lee, Kitty Law, Daisy Lam
INTRODUCTION: A substantial survival benefit with chemohormonal therapy has been proven by the CHAARTED and STAMPEDE studies, and this clinical approach has emerged as the standard of care for patients with metastatic hormone-naïve prostate cancer (mHSPC). However, because its clinical efficacy and tolerability in Asian patients remains uncertain, this study aims to evaluate preliminary results of its use in Hong Kong. METHODS: The clinical records of mHSPC patients treated with chemohormonal therapy from all six public oncology centers in Hong Kong between January 2015 and July 2016 were reviewed...
April 16, 2018: Asia-Pacific Journal of Clinical Oncology
Eleanor M Birch, Margaret M Haigh, Siddhartha Baxi, Marilyn Lyford, Shelley Cheetham, Shaouli Shahid, Sandra C Thompson
AIM: The aim of this study was to examine stakeholders' views of how the establishment of the South West Radiation Oncology Service in Bunbury, Western Australia, has affected treatment decision-making, and the extent to which patients are involved in the decision-making process. METHODS: Semi-structured in-depth interviews were undertaken with 21 service providers involved in the treatment and care of people with cancer, and 17 adults diagnosed with cancer who opted to undergo radiotherapy (RT) treatment at the Service...
March 26, 2018: Asia-Pacific Journal of Clinical Oncology
Rama Rao Malla, Santhi Pandrangi, Seema Kumari, Murali Mohan Gavara, Anil Kumar Badana
Exosomes are cell-cell communicators emerging as a new paradigm for noninvasive diagnosis and prognosis of treatment response. Exosomal tetraspanin proteins like CD63, CD9 and CD81 play a critical role in sorting, selective recruitment of biomolecules, target selection, cell-specific entry, capturing, angiogenesis and vasculogenesis. These tetraspanins are being used as markers for oral, colorectal and colon cancers and glioblastoma. However, exosomal markers with robust specificity for early detection of carcinomas are the furthest along...
March 25, 2018: Asia-Pacific Journal of Clinical Oncology
Di Wu, Li Liang, Ligong Nie, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Tao Xin, Jian Fang
AIM: Patients with advanced nonsquamous nonsmall cell lung cancer (NSCLC) who experienced progression with two or more lines chemotherapy have no treatment options that clearly confer a survival benefit. As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, apatinib has a certain antitumor effect for various solid tumors. The present study evaluated the efficacy and safety of apatinib in advanced nonsquamous NSCLC as salvage treatment in Chinese real-world practice...
March 24, 2018: Asia-Pacific Journal of Clinical Oncology
Elizabeth A Fradgley, Shu Er Chong, Martine E Cox, Craig Gedye, Christine L Paul
BACKGROUND: Many biobanks rely upon patients' willingness to donate biospecimens and healthcare professionals to initiate opt-in consent processes. This study explored if: (1) patients accept opt-in or opt-out consent models with varying levels of professional involvement; (2) professionals discuss participation with specific patient groups; and (3) this discussion is associated with patient knowledge of biobanking processes. METHODS: Outpatients completed surveys at a tertiary cancer center in New South Wales, Australia...
March 23, 2018: Asia-Pacific Journal of Clinical Oncology
Monica I Dumbrava, Elizabeth A Burmeister, David Wyld, David Goldstein, Dianne L O'Connell, Vanessa L Beesley, Helen M Gooden, Monika Janda, Susan J Jordan, Neil D Merrett, Madeleine E Payne, Mary A Waterhouse, Rachel E Neale
AIM: Palliative chemotherapy improves symptom control and prolongs survival in patients with unresectable pancreatic cancer, but there is a paucity of data describing its use and effectiveness in everyday practice. We explored patterns of chemotherapy use in patients with unresected pancreatic cancer in Australia and the impact of use on survival. METHODS: We reviewed the medical records of residents of New South Wales or Queensland, Australia, diagnosed with unresectable pancreatic adenocarcinoma between July 2009 and June 2011...
March 23, 2018: Asia-Pacific Journal of Clinical Oncology
Yisheng Wei, Xiao Zhang, Guoying Wang, Yaguang Zhou, Minrui Luo, Shan Wang, Chuyuan Hong
AIM: The effects of circulating eosinophils and basophils on cancer survival are unclear. Here, we aimed to explore the impacts of eosinophils and basophils on prognosis of stage I-III colorectal cancer (CRC) patients. METHODS: From February 2003 to March 2013, 569 stage I-III CRC patients were enrolled in this retrospective study. The associations between pretreatment circulating eosinophils, basophils and CRC overall survival (OS), disease-free survival (DFS) were investigated...
March 12, 2018: Asia-Pacific Journal of Clinical Oncology
Lisiane Silveira Zavalhia, Aline Weber Medeiros, Andrew Oliveira Silva, Adriana Vial Roehe
The fragile histidine triad (FHIT) gene encloses an active common chromosomal fragile site, FRA3B. This gene is known to be associated with genomic instability, apoptosis and DNA damage. FHIT disturbances have been related to carcinogenesis in different types of human tumor. Despite this, there are some controversies about the exact role of the FHIT gene in relation to tumor biology. Several pieces of evidence support the hypothesis that FHIT acts as a tumor suppressor gene. A loss or decrease in the Fhit protein expression appears to be related to tumor progression, poor prognostic factors and lower survival rates...
March 8, 2018: Asia-Pacific Journal of Clinical Oncology
Yu-Lin Lin, Ruey Kuen Hsieh, Chao-Hsiun Tang
AIM: Pain assessment and management have been important criteria in hospital accreditation in Taiwan since 2007. We used a Taiwanese health insurance database to determine factors influencing patterns of strong opioid use in cancer patients in their final 12 months of life. METHODS: Data from patients with cancer in Taiwan outpatient clinics with cancer-related deaths between 2008 and 2011 were included in the analysis. Strong opioid prescription data from the last 12 months of each patient's life, as well as patient, physician, and hospital characteristics, were collected from the National Health Insurance Research Database...
March 2, 2018: Asia-Pacific Journal of Clinical Oncology
Thiru Prasanna, Jane Beith, Steven Kao, Michael Boyer, Catriona M McNeil
Toxicities of systemic cancer therapies are often less frequently observed in clinical trials than in clinical practice, due to the careful selection of patients with fewer comorbidities. Although guidelines exist for the estimation of chemotherapy dose, clinical factors like age, comorbid illness and extremes of body habitus are not considered in the method of dose calculation, which can result in significant toxicity. We reviewed the referenced clinical trials from which the evidence-based curative-intent cancer treatment protocols were developed for EVIQ, which is an Australian government, online resource...
March 2, 2018: Asia-Pacific Journal of Clinical Oncology
Joe Jabbour, James Wykes, Chris Milross, Puma Sundaresan, Ardalan Ebrahimi, Heather L Shepherd, Haryana M Dhillon, Jonathan R Clark
BACKGROUND: Providing appropriate educational resources to patients with head and neck cancer (HNC) is important but challenging. The aim of this study was to determine Australian clinicians' perceptions of currently used HNC information resources. METHODS: A purpose-designed questionnaire was disseminated electronically to clinician members of the Australian and New Zealand Head and Neck Cancer Society (ANZHNCS) and The Australian Society of Otolaryngology Head and Neck Surgery (ASOHNS)...
March 2, 2018: Asia-Pacific Journal of Clinical Oncology
Yasuko Kikuchi, Yoshihiro Uchida, Kazuo Shirakawa, Hajime Kanauchi, Takayoshi Niwa, Kotoe Nishioka, Keiichirou Tada, Masanori Hashimoto, Hidemitsu Yasuda, Ryoko Sugiura, Hidetaka Kawabata, Yasuyuki Seto, Toshihisa Ogawa
AIM: This multicenter, observational study aimed to investigate the survival benefit of eribulin as well as that of taxane-based regimens in Japanese patients with metastatic breast cancer (MBC) in a real-world setting. METHODS: This study enrolled women with MBC who received eribulin or taxane-based regimens with or without bevacizumab in routine clinical practice from July 2011 to March 2014. Patients were followed until September 2015. The primary endpoint was overall survival (OS)...
March 1, 2018: Asia-Pacific Journal of Clinical Oncology
Crescens Tiu, Annie Wong, Alan Herschtal, Linda Mileshkin
AIM: To characterize the outcomes of patients with nonmelanoma solid tumors receiving anti-PD-1 immunotherapy not funded by the Australian Pharmaceutical Benefits Scheme. METHODS: Medical records of patients with metastatic nonmelanoma tumor diagnoses treated with anti-PD-1 (self-funded pembrolizumab or nivolumab through an access program) from January 1, 2014, to December 31, 2016, at Peter MacCallum Cancer Centre, were retrospectively reviewed. Events after December 31, 2016, were censored...
March 1, 2018: Asia-Pacific Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"